Evidence map›Paper›PMID 33878844›Full record

ReviewRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia2021

[Post-COVID syndrome: A reflection and opinion paper].

E Bouza, R Cantón Moreno, P De Lucas Ramos, A García-Botella, A García-Lledó, J Gómez-Pavón, J González Del Castillo, T Hernández-Sampelayo, M C Martín-Delgado, F J Martín Sánchez and 8 more

Open access · diamondAbstract readReview
In one paragraph

Review in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Insights for COVID-19 in 2023.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023
    Review
  9. Useful tools in post-COVID syndrome evaluation.Medicina clinica (English ed.) · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 2 countries.

E BouzaServicio de Microbiología Clínica y Enfermedades Infecciosas del Hospital General Universitario Gregorio Marañón, Universidad Complutense. CIBERES. Ciber de Enfermedades Respiratorias. Madrid, Spain. emilio.bouza@gmail.com.
R Cantón Moreno
P De Lucas Ramos
A García-Botella
A García-Lledó
J Gómez-Pavón
J González Del Castillo
T Hernández-Sampelayo
M C Martín-Delgado
F J Martín Sánchez
M Martínez-Sellés
J M Molero García
S Moreno Guillén
F J Rodríguez-Artalejo
J Ruiz-Galiana
S De Pablo Brühlmann
J Porta Etessam
M Santos Sebastián
Hospital General Universitario Gregorio Marañón · ESHospital Clínico San Carlos · ESHospital Ruber Internacional · ESHospital Universitario Príncipe de Asturias · ESInstituto Ramón y Cajal de Investigación Sanitaria · ESSociedad Andaluza de Medicina Familiar y Comunitaria · ESUniversidad Alfonso X el Sabio · ESUniversidad de Alcalá · ESUniversidad Francisco de Vitoria · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A high proportion of people who have suffered from COVID-19 report, after recovery from the acute phase of the disease, clinical manifestations, both subjective and objective, that continue beyond 3 weeks or even 3 months after the original clinical disease. There is still no agreed nomenclature to refer to this condition, but perhaps the most commonly used is post-COVID syndrome. The Scientific Committee on COVID of the Madrid College of Physicians (ICOMEM) has discussed this problem with a multidisciplinary approach in which internists, infectious disease specialists, psychiatrists, pneumologists, surgeons, geriatricians, pediatricians, microbiologists, family physicians and other specialists have participated, trying to gather the existing information and discussing it in the group. The clinical manifestations are very variable and range from simple fatigue to persistent fibrosing lung lesions with objective alterations of pulmonary function. Post-COVID syndrome seems to be particularly frequent and severe in adults who have required admission to Intensive Care Units and has a peculiar behavior in a very small group of children. The post-COVID syndrome, which undoubtedly exists, is at first sight not clearly distinguishable from clinical manifestations that which occur after other acute viral diseases and after prolonged stays in ICUs due to other diseases. Therefore, it offers excellent research opportunities to clarify its pathogenesis and possibly that of other related entities. It is possible that progressively there will be an increased demand for care among the millions of people who have suffered and overcome acute COVID for which the health authorities should design mechanisms for the agile management of care that will possibly require well-coordinated multidisciplinary groups. This paper, structured in questions on different aspects of the post-COVID syndrome, attempts to stage the current state of this problem.

Indexed as

AdultChildCOVID-19Critical CareHumansLungPost-Acute COVID-19 SyndromeCOVID-19post-COVID syndromepost ICU syndrome (PICUS)prolonged COVID

Identifiers

PMID33878844
PMCPMC8329562
OpenAlexW3155464349

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.